EX-21.1 5 prophase-exhibit21110xk2022.htm EX-21.1
EXHIBIT 21.1
SUBSIDIARIES OF PROPHASE LABS, INC.

|  | State or other |  |  |  |
|  | Jurisdiction of |  |  | Ownership |
Subsidiaries |  | Incorporation |  |  | Percentage |
Nebula Genomics, Inc. |  | Delaware |  |  |  | 100 | %
Pharmaloz Manufacturing Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Digital Media, Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Biopharma, Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Diagnostics, Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Diagnostics NJ, Inc. |  | New York |  |  |  | 100 | %
ProPhase Diagnostics NY, Inc. |  | Delaware |  |  |  | 100 | %
Quigley Pharma Inc. |  | Delaware |  |  |  | 100 | %
TK Supplements, Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Precision Medicine, Inc. |  | Delaware |  |  |  | 100 | %
ProPhase Global Healthcare, Inc. |  | Delaware |  |  |  | 100 | %

The above subsidiaries are included in the consolidated financial statements for the year ended December 31, 2022.